including DNA damage repair and cell cycle checkpoint activation. Considerable evidence also indicates a role for BRCA1 in transcriptional regulation [5, 6] . BRCA1 is present in a variety of multiprotein complexes involved in DNA repair, transcription and chromatin remodeling. In these processes it may act, at least in part, as a scaffolding protein or as a regulator of protein stability via its RING finger motif which has ubiquitin ligase activity [5] .
Livingston and colleagues [1] have now shown that there is a relationship between BRCA1 and X-inactivation (Figure 1 ). Immunofluorescence analysis revealed that, in a subset of female cells, XIST RNA co-localised with BRCA1 presumably reflecting an interaction (either direct or indirect) between the two molecules. This observation was supported by biochemical analysis. However, in tumours and cell lines lacking wildtype BRCA1, XIST failed to form Xi-associated foci. Other markers of the Xi such as H3mK9, mH2A1 incorporation and asynchronous replication of the two X chromosomes were also missing in the absence of functional BRCA1. These phenotypic indicators of loss of X-inactivation were accompanied by apparent reactivation of transcription from Xi as measured by an increase in the expression of an X-linked gene. Strong evidence for the critical role of BRCA1 in the X-inactivation process was provided by two observations. First, depletion of BRCA1 using RNA interference was accompanied by the loss of Xi-associated XIST foci. Second, reconstitution of a BRCA1 mutant cell line with wild-type BRCA1 led to the reformation of XIST foci in the majority of cells.
Independent support for a function for BRCA1 in keeping the Xi silent has come from tumour gene expression microarray data [7] . The finding of differential expression of these X-chromosomal genes between BRCA1-and BRCA2-associated ovarian cancers is relevant, because BRCA2 had no effect on the localisation of XIST domains and seems not to be important for X-inactivation [1] . Dosage compensation systems, of which X-inactivation is one type, appear to have evolved independently in many animal species that have heteromorphic sex chromosomes [8] . For example, in Drosophila, dosage compensation results in two-fold upregulation of the single X chromosome in males instead of the inactivation of a single X in females, as occurs in mammals. Despite this, there are some similarities between the Drosophila dosage compensation system and mammalian X-inactivation systems. Importantly, in both systems, non-coding RNAs (Rox and XIST) are critical to the process (Table 1) . Both BRCA1 and a binding partner BARD1 are RINGdomain-containing proteins that may be functionally analogous to the RING proteins MSL2 and MOF, components of the Drosophila dosage compensation complex [9, 10] . Furthermore, BRCA1 interacts with RNA helicase A, the mammalian orthologue of MLE. Given these striking comparisons it would be interesting to know whether these and other BRCA1-interacting proteins are also involved in X-inactivation. This might reflect a broader role for BRCA1 in regulating heterochromatin in general rather than in X-inactivation specifically. If this is the case there will be significant implications for the tumour suppressor function of BRCA1.
These new data reveal a novel link between X-chromosome activity and cancer. Furthermore, it might provide a mechanistic framework for understanding some pieces of evidence that have previously suggested this connection. These come from three areas of study: the Barr body, Klinefelter's syndrome and non-random inactivation. First, the Barr body (the cytologically visible Xi) was found to be reduced in frequency in breast cancers compared with normal tissue [11] and this was associated with poor prognosis [12] . Second, breast cancer occurs only rarely in men but a 47, XXY genotype (Klinefelter's syndrome) confers a 50-fold increased risk compared with XY men [13] . However, this seems likely to be associated with hormonal dysfunction rather than the presence of two X chromosomes particularly as 47, XXX women have no increased risk [14] . Third, the normal random nature of X-inactivation appears to be altered in BRCA1 mutation carriers that are susceptible to cancer [15, 16] .
The exact mechanism whereby reactivation of the Xi might influence tumourigenic progression is yet to be clarified. Nevertheless, the new role for BRCA1 in silencing the X chromosome is likely to open up exciting avenues of investigation in both cancer research and the epigenetic regulation of gene expression. 
